



RESEARCH CONFERENCES

ESF-EMBO Symposium

Antiviral Applications of RNA Interference

Hotel Eden Roc, Sant Feliu de Guixols (Costa Brava) • Spain
5-10 April 2008

Chair: **Jens Kurreck**, University of Stuttgart, DE
Co-Chair: **Ben Berkhout**, University of Amsterdam, NL


www.esf.org/conferences/08254

With support from:



QIAGEN

Oxford Journals



© Ebbe Sloth Andersen

www.esf.org

Final Programme

Saturday 05 April

Late afternoon / early evening	Registration at the ESF-RC desk
19.00	Welcome Drink
20.00	Supper

Sunday 06 April

08.45-09.00	Conference Opening (Jens Kurreck, Ben Berkhout)
-------------	---

Session 1: RNAi Technology

Chair: Jens Kurreck, Stuttgart, DE

09.00-09.35	Mark Kay Stanford University, US <i>RNAi based therapeutics for viral hepatitis and mechanisms of microRNA mediated translational silencing</i>
09.35-10.10	Jorgen Kjems University of Aarhus, DK <i>Optimization of siRNA function, in vivo delivery and therapeutic potential by chemical modifications and polymeric formulation</i>
10.10-10.40	Coffee break
10.40-11.15	Joerg Dennig Qiagen, DE <i>Efficient quantification of mammalian microRNA by a novel RT-PCR approach</i>
11.15-11.35	Puri Fortes CIMA/UNAV Pamplona, ES <i>Comparison between RNAi and RNAu</i>
11.35-11.55	Joachim Engels Goethe University Frankfurt, DE <i>Cationic siRNAs for stability and uptake</i>
12.00	Lunch

Session 2: Plant viruses

Chair: Jean-Luc Imler, Strasbourg, FR

14.15-15.50	TBA
15.50-15.10	Discussion
15.10-15.30	Björn Krenz University of Stuttgart, DE <i>Abutilon mosaic virus as a stable and attenuated vector for phloem-specific protein expression and virus-induced gene silencing</i>
15.30-15.35	Short Break

15.35-16.10	Juan Antonio Garcia University of Madrid, ES <i>RNA silencing suppression via sequestration of small RNAs by different proteins of viruses of the family Potyviridae</i>
16.10-16.30	Kirsi Lehto University of Turku, FI <i>Interference of different viral silencing suppressors with the wild-type Tobacco mosaic virus (TMV) infection and with different TMV-based constructs expression either the GFP marker or the ChlH endogene</i>
16.30-17.00	Coffee break

Session 3: Drosophila

Chair: Bryan Cullen, Duke, US

17.00-17.35	Jean-Luc Imler CNRS, FR <i>RNAi and innate antiviral immunity in the drosophila model</i>
17.35-18.10	Carla Saleh Institut Pasteur, FR <i>RNAi: the antiviral defence system in insects</i>
18.10-18.30	Ronald van Rij Radboud University Medical Center, NL <i>Discordant antiviral function of RNAi in Drosophila melanogaster and mammals</i>
19.00	Dinner
20.30-22.00	Poster Session

Monday 07 April

Session 4: Virus-host interactions / miRNAs

Chair: John Rossi, City of Hope, US

9.00-9.35	Goran Akusjarvi Uppsala University, SE <i>Adenoviral interference with the RNAi/miRNA pathways in human cells</i>
9.35-10.10	Bryan Cullen Duke University, US <i>Virally encoded miRNAs</i>
10.10-10.30	Fatah Kashanchi George Washington University, US <i>HIV-1 TAR miRNA, latency and cellular gene expression</i>
10.30-11.00	Coffee break
11.00-11.35	Olivier Voinnet CNRS, FR <i>Induction, suppression and usurpation of RNA silencing pathways by plant pathogens</i>
11.35-12.10	Kuan-Teh Jeang NIH, US <i>HIV-1 interaction with the host RNAi machinery</i>

12.10-12.30	Oscar Aparicio University of Navarra, ES <i>Adenovirus VA RNA is processed to functional miRNAs that target several cellular genes and affect virus production</i>
12.30	Lunch
Afternoon	Siesta
15.30-16.00	Coffee

Session 4: Virus-host interactions / miRNAs (continued)

16.00-16.35	Monsef Benkirane Institut de Génétique Humaine, FR <i>Interplay between RNAi effectors and HIV-1 replication</i>
16.35-17.10	Joost Haasnoot University of Amsterdam, NL <i>RNAi suppressor proteins from HIV-1, influenza virus and Ebolavirus</i>
17.10-17.20	Short Break

Session 5: HIV

17.20-17.55	John Rossi City of Hope Beckman Research Institute, US <i>RNAi and combinatorial gene therapy for HIV in hematopoietic stem cell and T-cell gene therapy settings</i>
17.55-18.30	Olivier ter Brake University of Amsterdam, NL <i>How to avoid viral escape from RNAi therapy</i>
19.00	Dinner
20.00-21.30	Poster Session

Tuesday 08 April

Session 5: HIV (continued)

Chair: Kuan-Teh Jeang, NIH, US

09.00-09.35	Miguel Angel Martinez Fundacion IrsiCaixa, ES <i>Strategies to minimize HIV-1 escape from siRNA</i>
09.35-10.10	Karin Metzner University of Erlangen, DE <i>Targeting drug resistant HIV-1 by RNA interference</i>
10.10-10.30	Eduardo Pauls Fundacion IrsiCaixa, ES <i>Effective small interfering RNAs targeting alphaV integrin inhibit HIV-1 replication</i>
10.30-10.50	Anne Gatignol McGill University, CA <i>HIV obstructs the RNAi pathway but does not disrupt TRBP-Dicer-Ago2 interactions</i>

10.50-11.20	Coffee Break
Session 6: HBV / HCV	
Chair: Mark Kay, Stanford, US	
11.20-11.55	Gunther Hartmann University of Bonn, DE <i>Combining siRNA and immunostimulatory RNA for the treatment of hepatitis B virus</i>
11.55-12.15	Qiuwei Pan University of Rotterdam, NL <i>Can RNA interference (RNAi) combine with interferon-alpha in anti-HCV treatment</i>
12.30	Lunch
14.00 – 18.30	Half-day excursion to Girona
19.00	Dinner
20.00-21.00	Forward Look Plenary Discussion

Wednesday 09 April

09.00-09.35	Rainer Wessely Technical University Munich, DE <i>RNA interference to treat enteroviral diseases: current status and clinical perspectives</i>
09.35-10.10	Carolyn Coyne University of Pittsburgh, US <i>Using RNAi to dissect enterovirus entry and infection of polarized cell monolayers</i>
10.10-10.30	Sandra Pinckert Charité Berlin, DE <i>Treatment of cardiac coxsackievirus infection by viral vector mediated RNA interference and soluble Coxsackie-Adenovirus Receptor (CAR) – a critical comparison</i>
10.30-10.50	Jens Kurreck University of Stuttgart, DE <i>Inhibiting coxsackievirus B3 and Echovirus 30 by means of RNA interference</i>
10.50-11.20	Coffee Break
11.20-11.55	Thomas Rudel Max-Planck-Institute for Infection Biology, DE <i>RNAi applications to defeat bacterial and viral infections of the respiratory tract</i>
11.55-12.15	Discussion

12.30 Lunch

Afternoon Siesta

16.30-17.00 Coffee

Session 8: Clinical Development of RNAi

Chair: Ben Berkhout, Amsterdam, NL

17.00-17.35 TBA

17.35-18.10 Jörg Kaufmann

Silence Therapeutics, DE

Development of liposomal siRNA for RNAi mediated therapeutic applications

18.10-18.45 Discussion

18.45-19.00 Ben Berkhout

University of Amsterdam, NL

Closing Remarks

20.00 Get-together & Conference Dinner

Thursday 10 April

Breakfast & Departure